Thank you, Dan, and good morning, everyone. As a reminder, our full-year results include approximately five months of operations from P3 Technologies, which was acquired in November of 2023. I will begin on Slide 5. As you can see, we had strong growth for our fourth quarter of fiscal 2024 with sales of $49.1 million, which was a quarterly record. This was up 14%, or $6 million, over the prior year and included $1.2 million of incremental sales from P3. Sales of $27.2 million to the defense market were up 43% for the quarter. Also contributing to our overall sales growth was a 22% increase in aftermarket sales. Of note, our aftermarket sales, which was historically from the refining and petrochemical markets, now includes more meaningful defense aftermarket sales, given our expanded defense business and our efforts to provide full life cycle solutions for our customers. P3's contribution to sales to the space market helped to offset lower revenue due to the loss of a customer in April of 2023, due to its bankruptcy. Going forward, we have now cycled through that one customer's impact on our space business. U.S. sales for the quarter were 86% of total revenue, and it continues to reflect the magnitude of our US-based defense business. Looking at the full year, you can clearly see the effectiveness of our strategic initiatives. We achieved record sales of $185.5 million in fiscal 2024, which was up $28.4 million or 18% over fiscal 2023. In fact, our compound annual growth rate over the last two years was 23%. This growth has primarily been organic and has been driven by defense and aftermarket demand. Turning to Slide 6, gross margin expanded 930 basis points to 25.9% in the quarter and 570 basis points to 21.9% for the year. Both periods reflected higher volume and a related improved absorption. Higher margin aftermarket sales also played a role, as did margin accretive sales from the P3 acquisition. Lastly, we benefited through the year from improved execution and pricing on our defense contracts. Turning to Slide 7, you can see our strong performance is translating to our bottom line. I should point out that we have made a change to the way we calculate adjusted net income. Beginning in the fourth quarter of fiscal 2024, we no longer exclude the Barbara Nichols supplemental performance bonus. Prior period results have been adjusted to reflect this change on a comparable basis, and you can see a supplemental data sheet filed with the SEC and provided on our website for additional history of adjusted net income and adjusted net income per diluted share. Net income in the fourth quarter of $1.3 million compares with a net loss of $481,000 in the fourth quarter of 2023. This equated to $0.12 net income per share and $0.15 of adjusted net income per share for the fourth quarter of fiscal 2024. Full-year net income significantly improved to $4.6 million from just $367,000 in fiscal 2023. Earnings per share for fiscal 2024 was $0.42 and adjusted EPS was $0.63, a 163% increase over the prior year. Lower tax rates for the quarter and for the full year reflected higher tax credits available with higher income and increased investment in R&D. There was also some discrete tax expense recognized in last year's period, as well as a lower mix of income in higher rate foreign tax jurisdictions in the current year. On Slide 8 is adjusted EBITDA. Similar to adjusted net income, we have made some changes to the way we calculate adjusted EBITDA to remove the add back of the Barbara Nichols supplemental performance bonus. We are also now excluding non-cash equity-based compensation expense, which aligns more consistently with general practice. As with adjusted net income, prior period results have been adjusted to reflect these changes on a comparable basis. Fourth quarter adjusted EBITDA doubled to $3 million over the comparable 2023 period, while fiscal 2024 adjusted EBITDA increased 56% to $13.3 million. Despite higher SG&A, adjusted EBITDA margin expanded 180 basis points to 7.2% and puts us solidly on track to achieve our fiscal 2027 goal of low to mid-teen adjusted EBITDA margin. Turning the Slide 9, we had a strong year of cash generation of $28.1 million or more than double fiscal 2023. This further improved our balance sheet, while still making strategic investments, both organically and inorganically. During the year, we paid off our remaining outstanding debt, which included borrowings in support of the P3 acquisition. We continued to have access to a $50 million revolving credit facility, which was amended during the past year to provide greater flexibility to fund our long-term strategic growth goals and reduced our costs. Capital expenditures of $9.2 million in the year were focused on capacity expansion, productivity improvements, including factory automation, and the start of the ERP implementation at our Batavia facility. CapEx for fiscal 2025 is expected to be between $10 million to $15 million, of which approximately half is related to the expansion of our Batavia facility for our defense business. I should point out that this will also benefit our commercial business. If you'll now turn to Slide 10, you'll see we had record orders in fiscal 2024 of $268 million, an increase of 32% over the prior year. Our book-to-bill ratio was an impressive 1.4 times. 66% of the orders, or $177.4 million, were largely follow-on orders for critical U.S. Navy programs. Notably though, orders for the petrochemical market increased 55%, while space orders improved 11% to $16.8 million, helped by the addition of P3. Turning to Slide 11, you'll see that our backlog was up 30% over fiscal 2023, providing several years of visibility given the long lead times of some of our defense contracts. The P3 acquisition added about $6 million to our backlog. The decline on a sequential basis is to be expected as our long lead defense orders tend to be lumpy. Approximately 35% to 40% of our backlog is expected to convert to sales in fiscal 2025 and another 25% to 30% is expected to convert to sales over the following 12 months. The majority of orders that convert beyond 12 months are for the defense industry, specifically the US Navy. Slide 12 highlights our guidance for fiscal 2025. Given the addition of P3 and our record level of orders, we are expecting revenue to be between $200 million and $210 million for fiscal 2025. This implies top-line growth of 11% at the midpoint of that range. From a margin perspective, we expect continued expansion of our gross margin to a range of 22% to 23%. Additionally, our expectation for SG&A, including amortization, is to be between 16.5% to 17.5% of sales. This includes costs associated with the Barbara Nichols supplemental bonus, equity-based compensation, and ERP conversion costs of approximately $6.5 million to $7.5 million. The net result is that we expect adjusted EBITDA for fiscal 2025 to be between $16.5 million to $19.5 million, which implies a 35% increase at the midpoint. The range also implies an adjusted EBITDA margin of 9% at the midpoint, or nearly 200 basis point improvement over this past fiscal year. I should point out that our adjusted EBITDA guidance reflects our revised method of determining adjusted EBITDA and only excludes equity-based compensation and ERP conversion costs from EBITDA, but not the Barbara Nichols supplemental performance bonus. We are delivering continuous improvement and are solidly on track to achieve our long-term fiscal 2027 financial goals. We continue to expect 8% to 10% annualized organic revenue growth per year, which implies $240 million to $250 million in revenue for fiscal 2027, based off our fiscal 2025 guidance we just provided. And with margins improving steadily, we believe we are on track to achieve our low to mid-teen adjusted EBITDA margin goal. With that, I will pass the call back to Dan.